BeiGene
BeiGene, Ltd. is a biotechnology company engaged in the development and commercialization of targeted and immuno-oncology therapeutics for cancer treatment. The company operates primarily in China and the United States, offering a range of commercial products including BRUKINSA for mantle cell lymphoma and Tislelizumab for classical Hodgkin's lymphoma. BeiGene's pipeline includes various clinical-stage drug candidates such as Zanubrutinib, an inhibitor for multiple lymphomas, and Pamiparib, a PARP inhibitor for solid tumors. The company also focuses on developing innovative treatments for diverse malignancies, such as acute myeloid leukemia, breast cancer, and non-small cell lung cancer. Its collaborations with multiple pharmaceutical companies enhance its capability to deliver affordable and accessible cancer therapies. Founded in 2010 and headquartered in Beijing, BeiGene aims to address significant unmet medical needs in oncology through its comprehensive portfolio of products and ongoing research initiatives.
Duo Oncology develops a new nanoparticle technology specially tailored to penetrate established tumors. Duo Oncology operates as a lean pharma business. The company works hand-in-hand with world-class university scientists and medical oncologists to develop their products through a network of established research organizations with the greatest possible speed and efficiency.
Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer.
BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.
Leap Therapeutics is a clinical-stage biopharmaceutical company and specializes in the development of targeted and immuno-oncology therapeutics. Leap Therapeutic focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.